Table 2.
Survival data of the eligible studies in this meta-analysis
| Author | Year | Tumor type | Sample size | Survival analysis | Multivariate analysis | HR statistic | Hazard ratios(95% CI) | RNA extraction | Reference control | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OS | PFS | OS | PFS | ||||||||
| Zheng JF | 2016 | PC | 96 | Yes | Yes | Yes | Data in paper | 2.292 (1.370-3.528) | 2.276 (1.199-2.768) | TRIzol(Invitrogen) | GAPDH |
| Chen SF | 2016 | SCLC | 112 | Yes | NA | Yes | Data in paper | 2.034 (1.216-3.402) | NA | RNAiso Plus (TAKARA) | GAPDH |
| Huang SY | 2016 | OC | 109 | Yes | NA | Yes | Data in paper | 2.938 (1.526-5.873) | NA | TRIzol(Invitrogen) | GAPDH |
| Wang CY | 2015 | GC | 85 | Yes | Yes | Yes | Data in paper | 2.405 (1.194-5.417) | 2.315 (1.097-5.283) | TRIzol(Invitrogen) | GAPDH |
| Chen X | 2015 | CSCC | 123 | Yes | Yes | Yes | Data in paper | 2.813 (1.504-6.172) | 3.072 (1.716-8.174) | TRIzol(Invitrogen) | GAPDH |
| Zhang XL | 2015 | ESCC | 227 | Yes | NA | Yes | Data in paper | 1.432 (1.005-2.041) | NA | Total Nucleic Acid Isolation Kit (Ambion) | RNU6B |
| Cai Y | 2015 | BC1 | 67 | Yes | NA | No | Survival curve | 3.87 ( 1.57-9.50 ) | NA | TRIzol(Thermo) | GAPDH |
OS Overall survival, PFS progression free survival, PC prostate cancer, SCLC small cell lung cancer, OC Ovarian cancer, GC gastric cancer, CSCC cervical squamous cell cancer, BC1 breast cancer, ESCC esophageal squamous cell carcinoma, Y Yes, NA not available, 95%CI 95% confidence interval.